Brief Cognitive Tests for Distinguishing Clinical Alzheimer-Type Dementia From Mild Cognitive Impairment or Normal Cognition in Older Adults With Suspected Cognitive Impairment
- PMID: 32340040
- DOI: 10.7326/M19-3889
Brief Cognitive Tests for Distinguishing Clinical Alzheimer-Type Dementia From Mild Cognitive Impairment or Normal Cognition in Older Adults With Suspected Cognitive Impairment
Abstract
Background: The accuracy and harms of brief cognitive tests for identifying clinical Alzheimer-type dementia (CATD) are uncertain.
Purpose: To summarize evidence on accuracy and harms of brief cognitive tests for CATD in older adults with suspected cognitive impairment.
Data sources: Electronic bibliographic databases (from inception to November 2019) and systematic review bibliographies.
Study selection: English-language, controlled observational studies in older adults that evaluated the accuracy of brief cognitive tests (standalone tests; memory, executive function, and language tests; and brief multidomain batteries) for distinguishing CATD from mild cognitive impairment (MCI) or normal cognition as defined by established diagnostic criteria. Studies with low or medium risk of bias (ROB) were analyzed.
Data extraction: Two reviewers rated ROB. One reviewer extracted data; the other verified extraction accuracy.
Data synthesis: Fifty-seven studies met analysis criteria. Many brief, single cognitive tests were highly sensitive and specific for distinguishing CATD from normal cognition. These included standalone tests (clock-drawing test, median sensitivity 0.79 and specificity 0.88 [8 studies]; Mini-Mental State Examination, 0.88 and 0.94 [7 studies]; Montreal Cognitive Assessment, 0.94 and 0.94 [2 studies]; and Brief Alzheimer Screen, 0.92 and 0.97 [1 study]), memory tests (list delayed recall, 0.89 and 0.94 [5 studies]), and language tests (category fluency, 0.92 and 0.89 [9 studies]). Accuracy was lower in distinguishing mild CATD from normal cognition and distinguishing CATD from MCI. No studies reported on testing harms.
Limitations: Studies were small. Few test metrics were evaluated by multiple studies. Few studies directly compared different tests, scores, cut points, or test combinations.
Conclusion: Many brief, single cognitive tests accurately distinguish CATD from normal cognition in older adults but are less accurate in distinguishing mild CATD from normal cognition or CATD from MCI. No studies reported on testing harms.
Primary funding source: Agency for Healthcare Research and Quality. (PROSPERO: CRD42018117897).
Keywords: Cognition; Cognitive impairment; Cohort studies; Dementia; Elderly; Longitudinal studies; Memory recall; Retrospective studies; Sensitivity; Specificity.
Comment in
-
Physicians and Alzheimer Dementia: Past, Present, and Future.Ann Intern Med. 2020 May 19;172(10):695-696. doi: 10.7326/M20-1500. Epub 2020 Apr 28. Ann Intern Med. 2020. PMID: 32340036 No abstract available.
Similar articles
-
Diagnosis and Treatment of Clinical Alzheimer’s-Type Dementia: A Systematic Review [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Apr. Report No.: 20-EHC003. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Apr. Report No.: 20-EHC003. PMID: 32369312 Free Books & Documents. Review.
-
Benefits and Harms of Prescription Drugs and Supplements for Treatment of Clinical Alzheimer-Type Dementia.Ann Intern Med. 2020 May 19;172(10):656-668. doi: 10.7326/M19-3887. Epub 2020 Apr 28. Ann Intern Med. 2020. PMID: 32340037
-
Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov. Report No.: 14-05198-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov. Report No.: 14-05198-EF-1. PMID: 24354019 Free Books & Documents. Review.
-
Accuracy of Biomarker Testing for Neuropathologically Defined Alzheimer Disease in Older Adults With Dementia.Ann Intern Med. 2020 May 19;172(10):669-677. doi: 10.7326/M19-3888. Epub 2020 Apr 28. Ann Intern Med. 2020. PMID: 32340038
-
Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Feb. Report No.: 19-05257-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Feb. Report No.: 19-05257-EF-1. PMID: 32129963 Free Books & Documents. Review.
Cited by
-
What Are the Reliable Plasma Biomarkers for Mild Cognitive Impairment? A Clinical 4D Proteomics Study and Validation.Mediators Inflamm. 2024 May 27;2024:7709277. doi: 10.1155/2024/7709277. eCollection 2024. Mediators Inflamm. 2024. PMID: 38883967 Free PMC article.
-
Alzheimer's disease and drug delivery across the blood-brain barrier: approaches and challenges.Eur J Med Res. 2024 Jun 8;29(1):313. doi: 10.1186/s40001-024-01915-3. Eur J Med Res. 2024. PMID: 38849950 Free PMC article. Review.
-
Alcohol Use Disorder and Dementia: A Review.Alcohol Res. 2024 May 23;44(1):03. doi: 10.35946/arcr.v44.1.03. eCollection 2024. Alcohol Res. 2024. PMID: 38812709 Free PMC article. Review.
-
Evaluating Cognitive Impairment in a Large Health Care System: The Cognition in Primary Care Program.J Alzheimers Dis. 2024;99(2):493-501. doi: 10.3233/JAD-231200. J Alzheimers Dis. 2024. PMID: 38701141 Free PMC article.
-
A Review on Tau Targeting Biomimetics Nano Formulations: Novel Approach for Targeting Alzheimer's Diseases.Cent Nerv Syst Agents Med Chem. 2024;24(3):294-303. doi: 10.2174/0118715249289120240321065936. Cent Nerv Syst Agents Med Chem. 2024. PMID: 38646682 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous